Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503481-23-00

Acronym

2021/3336

Enrollment

1666

Registered

2024-03-12

Start date

2023-03-20

Completion date

Unknown

Last updated

2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance treatment in metastatic non-squamous lung cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026